Laboratory Abnormality . | Dual Therapy (n = 126) . | Triple Therapy (n = 123) . | P Value . |
---|---|---|---|
Any grade 3 or 4 laboratory abnormality | 4 (3) | 4 (3) | .972 |
Alanine aminotransferase (>5 ×ULN) | 0 | 0 | |
Aspartate aminotransferase (>5 ×ULN) | 0 | 1 (1) | .310 |
Total cholesterol (>300 mg/dL) | 4 (3) | 3 (2) | .725 |
Triglycerides (>750 mg/dL) | 0 | 0 |
Laboratory Abnormality . | Dual Therapy (n = 126) . | Triple Therapy (n = 123) . | P Value . |
---|---|---|---|
Any grade 3 or 4 laboratory abnormality | 4 (3) | 4 (3) | .972 |
Alanine aminotransferase (>5 ×ULN) | 0 | 0 | |
Aspartate aminotransferase (>5 ×ULN) | 0 | 1 (1) | .310 |
Total cholesterol (>300 mg/dL) | 4 (3) | 3 (2) | .725 |
Triglycerides (>750 mg/dL) | 0 | 0 |
Data are number of patients with 1 or more adverse events (%).. Dual therapy = switching to darunavir/r + lamivudine. Triple therapy = maintain triple therapy with darunavir/r + 2 nucleos(t)ide reverse transcriptase inhibitors.
Abbreviation: ULN, upper limit of normal.
Laboratory Abnormality . | Dual Therapy (n = 126) . | Triple Therapy (n = 123) . | P Value . |
---|---|---|---|
Any grade 3 or 4 laboratory abnormality | 4 (3) | 4 (3) | .972 |
Alanine aminotransferase (>5 ×ULN) | 0 | 0 | |
Aspartate aminotransferase (>5 ×ULN) | 0 | 1 (1) | .310 |
Total cholesterol (>300 mg/dL) | 4 (3) | 3 (2) | .725 |
Triglycerides (>750 mg/dL) | 0 | 0 |
Laboratory Abnormality . | Dual Therapy (n = 126) . | Triple Therapy (n = 123) . | P Value . |
---|---|---|---|
Any grade 3 or 4 laboratory abnormality | 4 (3) | 4 (3) | .972 |
Alanine aminotransferase (>5 ×ULN) | 0 | 0 | |
Aspartate aminotransferase (>5 ×ULN) | 0 | 1 (1) | .310 |
Total cholesterol (>300 mg/dL) | 4 (3) | 3 (2) | .725 |
Triglycerides (>750 mg/dL) | 0 | 0 |
Data are number of patients with 1 or more adverse events (%).. Dual therapy = switching to darunavir/r + lamivudine. Triple therapy = maintain triple therapy with darunavir/r + 2 nucleos(t)ide reverse transcriptase inhibitors.
Abbreviation: ULN, upper limit of normal.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.